Beta-lactamases are bacterial enzymes that inactivate β-lactam antibiotics by hydrolysis, which results in ineffective compounds. One group of β-lactamases, extended-spectrum β-lactamases (ESBLs), are able to hydrolyze and cause resistance against a wide variety of novel β-lactams, including third-generation cephalosporins and monobactams, but not against cephamycins and carbapenems ([@b12-bjm-44-469]). ESBLs are common in hospitalized patients ([@b4-bjm-44-469]) and only a few studies have investigated the presence of these bacteria in community patients, especially urine cultures ([@b8-bjm-44-469]). The aim of the present study was to detect *bla*~TEM~ and *bla*~CTX-M~ genes by molecular methods in enterobacteria isolated from urine cultures of patients with community-acquired urinary infection and analyze their antimicrobial susceptibility profile.

A total of 5,672 consecutive urines samples were collected from a private diagnostic laboratory located in São Luís, Brazil between March and August, 2009. Of these, 916 were positive uropathogens, including 472 (51.5%) enterobacteria. Susceptibility testing was performed and interpreted by disk diffusion method ([@b3-bjm-44-469]) and Vitek 2 automated system (BioMérieux®, Marcy l'Etoile, France) for all enterobacteria.

The test was run against the following antibiotics: amoxicillin-clavulanic acid (AMC); aztreonam (AZT); ampicillin (AMP); ampicillin-sulbactam (SAM); amikacin (AMK); gentamicin (GEN); cefepime (CFP); cefotaxime (CFX); ceftazidime (CFZ); ceftriaxone (CTX); ciprofloxacin (CIP); levofloxacin (LVX); nitrofurantoin (NIT); piperacillin-tazobactam (TZP); trimethoprim-sulfamethoxazole (SXT); imipenem (IPM); meropenem (MEM); ertapenem (ERT). *Pseudomonas aeruginosa* ATCC 27853 and *E. coli* ATCC 25922 and ATCC 35218 were used as quality controls for antimicrobial susceptibility.

ESBL production was analyzed phenotypically by the combination disk method ([@b3-bjm-44-469]). For confirmation of ESBLs production, the isolates were interpreted by the disk approximation method and addition of clavulanic acid using cefotaxime/clavulanic acid and ceftazidime/clavulanic acid disks. *Klebsiella pneumoniae* ATCC 700603 and *E. coli* ATCC 25922 were used as positive and negative controls, respectively. Triplex PCR was used to determine the presence of *bla*~TEM~ and *bla*~CTX-M~ genes in ESBLs-producing Enterobacteriaceae isolates ([@b9-bjm-44-469]).

The prevalence of ESBL-producing Enterobacteriaceae in community-acquired urinary infections in southern Brazil is 1.5% ([@b8-bjm-44-469]), 3.5% in Italy ([@b7-bjm-44-469]) and 4.5% in Saudi Arabia ([@b6-bjm-44-469]). In this study, 7.6% (36/472) of the enterobacteria isolates were ESBLs-producers according to the phenotypical methods, demonstrating that the frequency of bacteria expressing the ESBL phenotype significantly varies from region to region. Other studies investigating the production of ESBLs in *E. coli* isolates also demonstrated the presence of this microorganism in the community ([@b2-bjm-44-469]; [@b5-bjm-44-469]; [@b13-bjm-44-469]; [@b15-bjm-44-469]).

All isolates ESBLs-producing were resistant to ampicillin, ampicillin-sulbactam, cephalosporins, and aztreonam. With the exception of *E. coli*, all the others microorganisms showed 100% resistance to ciprofloxacin, levofloxacin and nitrofurantoin, in addition to high resistance to gentamicin, trimethoprim-sulfamethoxazole and piperacillin-tazobactam ([Table 1](#t1-bjm-44-469){ref-type="table"}). Amikacin, imipenem, meropenem and ertapenem were the most effective antibiotics against the ESBL-producing strains.

Of the isolates, 97.2% (35/36) carried at least one of the genes investigated by PCR ([Table 2](#t2-bjm-44-469){ref-type="table"}). The frequency of the *bla*~TEM~ gene was 52.7% (19/36), whereas frequencies of 95% and 1% have been reported in studies conducted in southern Brazil ([@b8-bjm-44-469]) and Spain ([@b14-bjm-44-469]). The *bla*~CTX-M~ gene was detected in 80.5% (29/36) of the isolates and the simultaneous presence of the *bla*~TEM~ and *bla*~CTX-M~ genes was demonstrated in 36.1% (13/36) ([Table 2](#t2-bjm-44-469){ref-type="table"}). Although TEM and SHV type ESBLs are mainly identified in hospitalized patients, a growing number of community-acquired infections caused by CTX-M-producing species have been recently reported, especially the ones caused by *E. coli* ([@b5-bjm-44-469]; [@b11-bjm-44-469]). In addition to this specie, the present results show that the *bla*~CTX-M~ gene had high frequency in all isolates, except for *Enterobacter cloacae*. A significant presence of CTX-M-producing species among strains isolated from community patients has been reported in other studies conducted in Brazil ([@b8-bjm-44-469]), Cambodia ([@b15-bjm-44-469]), Canada ([@b10-bjm-44-469]), France ([@b1-bjm-44-469]) and Italy ([@b7-bjm-44-469]).

This is the first study to detect the presence of ESBL-producing Enterobacteriaceae in community-acquired urinary infections in São Luis, Brazil. The results demonstrate that other enterobacteria species produce ESBLs, such as *Enterobacter aerogenes*, *E. cloacae* and *Morganella morganii* ([Table 1](#t1-bjm-44-469){ref-type="table"}). This indicates the need to expand the phenotypic methods for these pathogens. Currently, these methods are standardized by the CLSI only for *E. coli*, *K. pneumoniae*, *K. oxytoca* and *P. mirabilis*. Given this lack of standardized phenotypic methods for detection of ESBLs for all enterobacteria, this study will contribute to a better understanding of the susceptibility of these pathogens.

Our data confirm that carbapenems remain active against these microorganisms. *E. coli* was the prevalent specie in the ESBL-producing strains isolated from urine culture of community patients and CTX-M the most frequent enzyme.

In summary, although clinicians need to be aware of the presence of ESBLs-producing Enterobacteriaceae in the community, public health control measures are needed to prevent the further spread of these pathogens.
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###### 

Antimicrobial resistance profile of the different ESBL-producing species.

  Species           No. of isolates   \% resistance                                                                                
  ----------------- ----------------- --------------- ------- ------- ------- ------- ------- ------- ------- ------- ------ ----- -----
  *E. coli*         20                100.0           100.0   6.6     16.7    72.3    80.0    35.0    11.2    89.9    0.0    0.0   0.0
  *K. pneumoniae*   10                100.0           100.0   10.0    70.0    100.0   100.0   100.0   60.0    90.0    10.0   0.0   0.0
  *E. cloacae*      3                 100.0           100.0   25.0    75.0    100.0   100.0   100.0   75.0    75.0    0.0    0.0   0.0
  *E. aerogenes*    1                 100.0           100.0   100.0   100.0   100.0   100.0   100.0   0.0     100.0   0.0    0.0   0.0
  *P. mirabilis*    1                 100.0           100.0   0.0     100.0   100.0   100.0   100.0   100.0   100.0   0.0    0.0   0.0
  *M. morganii*     1                 100.0           100.0   0.0     100.0   100.0   100.0   100.0   0.0     100.0   0.0    0.0   0.0

AMP: ampicillin; SAM: ampicillin-sulbactam; AMK: amikacin; GEN: gentamicin; CIP: ciprofloxacin; LVX: levofloxacin. NIT: nitrofurantoin; TZP: piperacillin-tazobactam; SXT: trimethoprim-sulfamethoxazole; IPM: imipenem; MEM: meropenem. ERT: ertapenem.

###### 

Detection of ESBL-coding genes by PCR according to species.

  Species           No. isolates   *bla*~TEM~   *bla*~CTX-M~
  ----------------- -------------- ------------ --------------
  *E. coli*         3              \+           −
                    13             −            \+
                    3              \+           \+
                    1              −            −
  *K. pneumoniae*   1              \+           −
                    3              −            \+
                    6              \+           \+
  *E. cloacae*      2              \+           −
                    1              \+           \+
  *E. aerogenes*    1              \+           \+
  *P. mirabilis*    1              \+           \+
  *M. morganii*     1              \+           \+
  Total             36             19 (52.7%)   29 (80.5%)
